Cargando…
SOLVx therapeutics vaccine – Activate T-cell immunity using broad surveillance epitope strategy against mutant strains SARS-COV2
Highly mutable Coronavirus-19 continuously reconstructs its genome and renders prophylactic vaccines ineffective. The objective of the present study was to demonstrate the anti-viral efficacy and safety of the SOLVx therapeutics vaccine. The peptides were designed with Neo7Logix R&D and synthesi...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The Author(s). Published by Elsevier Masson SAS.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9149046/ https://www.ncbi.nlm.nih.gov/pubmed/35653885 http://dx.doi.org/10.1016/j.biopha.2022.113212 |